SpringWorks Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...

Halozyme Therapeutics stock is trading -17.97% below its average target price of $64.12 after marking a 2.8% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of ...

FY25 consensus $4.69. Raises FY25 revenue view to $1.15B-$1.225B from $1.095B-$1.17B, consensus $1.16B.Stay Ahead of the Market:Discover ...

EST Halozyme (HALO) announces new $250M accelerated share repurchase plan Stay Ahead of the Market:Discover outperforming stocks and ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

January 05, 2025, 00:04 am ET, BY Joseph H.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.